Clinical Trials
4 trialsNCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT00795782 2016-04-15
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Samsung Medical Center
Phase 3 Completed
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn